Oct 5, 2017 1 min read

CANONSBURG – Mylan N.V. announced Thursday the U.S. launch of Moxifloxacin Hydrochloride in 0.8 percent Sodium Chloride Injection, 400 mg/250 mL (1.6 mg/mL) in 250 milliliter single-dose flexible bags, the first AP-rated generic version of Bayer’s Avelox.

The product is being marketed and distributed by Mylan’s subsidiary, Mylan Institutional, under a final approval from the U.S. Food and Drug Administration for an Abbreviated New Drug Application for the product. It is a fluoroquinolone antibacterial indicated for treating infections in adults caused by designated susceptible bacteria in community acquired pneumonia, skin and skin structure infections, complicated intra-abdominal infections, plague, acute bacterial sinusitis and acute bacterial exacerbation of chronic bronchitis.